Oculis (OCS) Competitors $18.06 -0.34 (-1.85%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$18.02 -0.04 (-0.22%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. VKTX, PTGX, MLTX, MTSR, KYMR, IMVT, MOR, CRNX, ALVO, and HCMShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Viking Therapeutics (VKTX), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Kymera Therapeutics (KYMR), Immunovant (IMVT), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Viking Therapeutics Protagonist Therapeutics MoonLake Immunotherapeutics Metsera Kymera Therapeutics Immunovant MorphoSys Crinetics Pharmaceuticals Alvotech HUTCHMED Oculis (NASDAQ:OCS) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk. Does the media refer more to OCS or VKTX? In the previous week, Viking Therapeutics had 6 more articles in the media than Oculis. MarketBeat recorded 10 mentions for Viking Therapeutics and 4 mentions for Oculis. Viking Therapeutics' average media sentiment score of 1.00 beat Oculis' score of 0.47 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk & volatility, OCS or VKTX? Oculis has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Which has better valuation and earnings, OCS or VKTX? Oculis has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K1,010.90-$97.43M-$2.64-6.84Viking TherapeuticsN/AN/A-$109.96M-$1.15-27.05 Is OCS or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Viking Therapeutics' return on equity of -14.41% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,788.70% -92.95% -70.03% Viking Therapeutics N/A -14.41%-14.02% Do analysts rate OCS or VKTX? Oculis currently has a consensus price target of $35.33, indicating a potential upside of 95.64%. Viking Therapeutics has a consensus price target of $87.15, indicating a potential upside of 180.15%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in OCS or VKTX? 22.3% of Oculis shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryViking Therapeutics beats Oculis on 12 of the 15 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$803.39M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-6.8420.5827.9620.25Price / Sales1,010.90292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book9.467.638.045.49Net Income-$97.43M-$55.05M$3.18B$250.27M7 Day Performance-4.72%8.54%3.68%4.80%1 Month Performance-8.23%5.51%4.10%7.68%1 Year Performance58.70%2.03%29.59%16.36% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.1969 of 5 stars$18.06-1.8%$35.33+95.6%+58.4%$803.39M$780K-6.842News CoverageVKTXViking Therapeutics4.505 of 5 stars$27.51-2.4%$87.15+216.8%-46.9%$3.17BN/A-23.9220PTGXProtagonist Therapeutics1.4839 of 5 stars$49.87-2.3%$66.10+32.5%+48.1%$3.16B$434.43M66.49120Positive NewsMLTXMoonLake Immunotherapeutics1.6889 of 5 stars$47.50-2.8%$74.50+56.8%+5.0%$3.13BN/A-20.652Positive NewsMTSRMetseraN/A$28.39-3.6%$55.00+93.7%N/A$3.09BN/A0.0081News CoverageGap DownKYMRKymera Therapeutics3.109 of 5 stars$43.81-2.2%$59.11+34.9%+14.1%$2.92B$47.07M-14.13170Analyst RevisionIMVTImmunovant1.2956 of 5 stars$16.42-3.1%$38.33+133.5%-40.2%$2.90BN/A-5.99120News CoverageAnalyst UpgradeGap DownMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.4575 of 5 stars$29.06-2.5%$71.75+146.9%-39.5%$2.79B$1.04M-7.61210News CoverageAnalyst ForecastALVOAlvotech2.6901 of 5 stars$9.02-1.8%$18.00+99.6%-28.5%$2.77B$491.98M24.381,032HCMHUTCHMED1.6159 of 5 stars$15.42-2.5%$19.00+23.2%-9.8%$2.76B$630.20M0.001,811Gap Down Related Companies and Tools Related Companies VKTX Competitors PTGX Competitors MLTX Competitors MTSR Competitors KYMR Competitors IMVT Competitors MOR Competitors CRNX Competitors ALVO Competitors HCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCS Stock Alerts